Clinical Trial Update: Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction [Phase 2]

View source ↗

Summary

Phase 2 trial investigating fosamprenavir for laryngopharyngeal reflux, focusing on tissue treatment and enzyme reduction; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngopharyngeal Reflux

Drugs mentioned

• Fosamprenavir (fosamprenavir)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Laryngopharyngeal Reflux | Phase 2 | Status: NOT_YET_RECRUITING